Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN 0401)
Website: https://web.emmes.com/study/bmt2
Parent Study Contact:
Alan Howard,
ahoward@nmdp.org
Study Type:
Clinical Trial
Prepared on May 31, 2012
Consent: Restricted Consent
Consent Restrictions: For protocol use only
Commercial Use Restrictions:
No
Collection Type: Proprietary Study
- See bottom of this webpage for request information
Objectives
The primary objective of this study is to compare progression-free survival (PFS) after autologous Hematopoietic stem cell transplantation (ASCT) for chemotherapy-sensitive diffuse large B-cell lymphoma using Rituxan/BEAM versus Bexxar/BEAM for pre-transplant conditioning.
Interested parties can contact Alan Howard for further details about specimen availability.